Adcirca and Hypernatraemia - a phase IV clinical study of FDA data

Summary:

Hypernatraemia is reported as a side effect among people who take Adcirca (tadalafil), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Remodulin, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Hypernatraemia when taking Adcirca. It is created by eHealthMe based on reports of 54,899 people who have side effects when taking Adcirca from the FDA, and is updated regularly.

What is Adcirca?

Adcirca has active ingredients of tadalafil. It is often used in pulmonary hypertension. eHealthMe is studying from 54,957 Adcirca users. Check the latest studies of Adcirca.

What is Hypernatraemia?

Hypernatraemia (an abnormally high plasma concentration of sodium ions) is found to be associated with 655 drugs and 805 conditions by eHealthMe. Check the latest studies of Hypernatraemia.

On Jul, 11, 2026

54,899 people reported to have side effects when taking Adcirca.
Among them, 17 people (0.03%) have Hypernatraemia.

Among these 17 people:

How long have people been on Adcirca when they have Hypernatraemia? *

What is the gender of people who have Hypernatraemia when taking Adcirca? *

female: 81.25 %
male: 18.75 %

What is the age of people who have Hypernatraemia when taking Adcirca? *

What are other drugs people take besides Adcirca? *

What are other side effects people have besides Hypernatraemia? *

Dyspnea (difficult or laboured breathing): 6 people, 35.29%
Fluid Retention (an abnormal accumulation of fluid in the blood): 5 people, 29.41%
Pneumonia: 5 people, 29.41%
Respiratory Tract Congestion (blockage on respiratory system): 4 people, 23.53%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 4 people, 23.53%
Cardiac Failure Congestive: 4 people, 23.53%
Hypervolaemia (abnormally increased volume of blood): 4 people, 23.53%
Renal Disorder (kidney disease): 4 people, 23.53%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 4 people, 23.53%
Dehydration (dryness resulting from the removal of water): 4 people, 23.53%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 13 people, 76.47%
Type 2 Diabetes: 1 person, 5.88%
Nausea (feeling of having an urge to vomit): 1 person, 5.88%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 1 person, 5.88%
High Blood Cholesterol: 1 person, 5.88%
Headache (pain in head): 1 person, 5.88%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 5.88%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 5.88%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 5.88%
Cor Pulmonale (enlargement of the right ventricle of the heart): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Adcirca and have Hypernatraemia?

- Check whether Hypernatraemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adcirca:

Adcirca (54,957 reports)

Hypernatraemia treatments and more:

Hypernatraemia (6,339 reports)

Browse all side effects of Adcirca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypernatraemia:

Hypernatraemia (655 drugs)

Browse all the conditions that are associated with Hypernatraemia:

Hypernatraemia (805 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tadalafil (the active ingredients of Adcirca) and Adcirca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.